Mobic Adds Juvenile RA Indication, Cardiovascular “Black Box” Warnings
Executive Summary
Addition of a juvenile rheumatoid arthritis indication to Boehringer Ingelheim's Mobic provided an opportunity to add class cardiovascular and gastrointestinal risk language to labeling for the nonsteroidal anti-inflammatory drug
You may also be interested in...
Relafen Labeling Revision Includes Stronger Renal Effects Precaution
The maximum starting dose of GlaxoSmithKline's Relafen in patients with moderate to severe renal insufficiency should not exceed 750 mg or 500 mg, respectively, according to revised labeling for the nonsteroidal anti-inflammatory drug
Relafen Labeling Revision Includes Stronger Renal Effects Precaution
The maximum starting dose of GlaxoSmithKline's Relafen in patients with moderate to severe renal insufficiency should not exceed 750 mg or 500 mg, respectively, according to revised labeling for the nonsteroidal anti-inflammatory drug
Pfizer Celebrex Revised Labeling Adds Class Cardio Risk, Moves Safety Data
Pfizer appears to have used the relabeling of its COX-2 inhibitor Celebrex to add class cardiovascular risk language as an opportunity to renegotiate the placement of safety data